Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Should You Buy?

Pharvaris (NASDAQ:PHVS - Get Free Report) shares saw an uptick in trading volume on Friday . 60,790 shares were traded during trading, a decline of 12% from the previous session's volume of 69,045 shares.The stock last traded at $16.26 and had previously closed at $15.83.

Wall Street Analyst Weigh In

Separately, JMP Securities boosted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research report on Friday, January 31st.

Pharvaris Price Performance

The business's fifty day simple moving average is $14.94 and its two-hundred day simple moving average is $18.08. The company has a market cap of $892.07 million, a PE ratio of -6.09 and a beta of -2.84.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings data on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.06. As a group, analysts predict that Pharvaris will post -2.71 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after purchasing an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Pharvaris during the fourth quarter worth about $64,000. Barclays PLC purchased a new stake in shares of Pharvaris during the third quarter worth about $106,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Pharvaris during the fourth quarter worth about $111,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Pharvaris during the fourth quarter worth about $152,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.